A Phase 3 interventional study of Crizotinib and Pemetrexed/Cisplatin in NSCLC (Non-small Cell Lung Cancer), sponsored by Pfizer. Completed at 47 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-12-08.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 3, and was the 6th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Hunan Province Tumor Hospital · Sites in China
Ages 18+ · Healthy volunteers
Hunan Province Tumor Hospital · Sites in China
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 207 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 23 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 33rd largest by enrollment of the 136 interventional ones that give a count, is one of 2 that started in 2012, is one of 18 in phase 3, and was the 52nd registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
2 of the studies testing crizotinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT06563999Sun Yat-sen UniversityNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, Randomized, Open-label, Efficacy and Safety Study of Crizotinib single agent versus Chemotherapy Regimens (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) in First-Line ALK (Anaplastic Lymphoma Kinase) Positive East Asian Non-Small Cell Lung Cancer Patients. The objective of the study is to demonstrate that Crizotinib is superior to first-line chemotherapy pemetrexed/cisplatin or pemetrexed/carboplatin in prolonging Progression Free Survival (PFS) in East Asian patients with advanced Non-Squamous NSCLC whose tumors harbor a translocation or inversion event involving the ALK (Anaplastic Lymphoma Kinase) gene locus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Crizotinib
Drug: Crizotinib
Chemotherapy \[Option at Investigator's Choice\]
Drug: Pemetrexed/Cisplatin · Drug: Pemetrexed/Carboplatin
250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
Drug pages: Pemetrexed · Cisplatin
Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
Drug pages: Pemetrexed · Carboplatin
Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
Progression-Free Survival (PFS) Based on IRR by Treatment Arm
PFS was defined as the time from the date of randomization to the date of the first documentation of objective tumor progression (by IRR) or death on study due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS (in months) was calculated as (first event date - randomization date +1)/30.44. Progression is defined using RECIST v1.1, as at least a 20% increase (including an absolute increase of at least 5 millimeters) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)
Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR
Percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (assessed up to 33 months)
Overall Survival (OS)
OS was defined as the time from randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - date of randomization +1)/30.44. For participants who were lost to follow-up or withdrew consent, the OS was censored on the last date that participants were known to be alive.
Time frame: From randomization to death or last date known as alive for those who were lost to follow-up or withdrew consent (assessed up to 64 months).
Percentage of Participants With Disease Control at 12 Weeks Based on IRR
Disease Control Rate (DCR) at 12 weeks is defined as the percent of participants with CR, PR or stable disease (SD) at 12 weeks according to RECIST version 1.1 as determined by the IRR. The best response of SD can be assigned if SD criteria were met at least once after randomization at a minimum interval of 6 weeks. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: From randomization to Week 12
Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months
Probability of survival 1 year and 18 month after randomization. The probability of survival at 1 year was estimated using the Kaplan Meier method and a 2-sided 95% CI for the log \[-log(1-year survival probability)\] was calculated using a normal approximation and then back transformed to give a CI for the 1-year survival probability itself. The probability of survival at 18 months was estimated similarly.
Time frame: From randomization to 1 year and from randomization to 18 months
Duration of Response (DR) Based on IRR
DR was defined as the time from the first documentation of objective tumor response (CR or PR), as determined by the IRR, to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR (in weeks) was calculated as (first date of PD or death - first date of CR or PR +1)/7. DR was only calculated for the subgroup of participants with an objective tumor response.
Time frame: From objective response to date of progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)
Time to Tumor Response (TTR) Based on IRR
TTR was defined as the time from randomization to first documentation of objective tumor response (CR or PR) as determined by the IRR. For participants proceeding from PR to CR, the onset of PR was taken as the onset of response. TTR was calculated for the subgroup of participants with objective tumor response.
Time frame: Randomization to first documentation of objective tumor response (up to 33 months).
Time to Progression (TTP) Based on IRR
TTP was defined as the time from the date of randomization to the date of the first documentation of objective tumor progression, as determined by IRR. If tumor progression data included more than 1 date, the first date was used. TTP (in months) was calculated as (first event date - randomization date +1)/30.44.
Time frame: Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)
Intracranial Time to Progression (IC-TTP) Based on IRR
IC-TTP was defined similarly to TTP, but only considering intracranial disease (excluding extracranial disease) and the progression was determined based on either new brain metastases or progression of existing brain metastases.
Time frame: Randomization to objective intracranial progression or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)
Extracranial Time to Progression (EC-TTP) Based on IRR
EC-TTP was defined similarly to TTP, but only considering extracranial disease (excluding intracranial disease) and the progression was determined based on either new extracranial lesions or progression of existing extracranial lesions.
Time frame: Randomization to objective extracranial progression or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)
Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough Assessed Using Quality of Life Questionnaire Supplement Module for Lung Cancer (QLQ-LC13)
The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. The QLQ-LC13 Coughing, Dyspnoea and Pain in chest each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems. TTD in pain in chest, dyspnea, or cough from the QLQ-LC13 was a composite endpoint defined as the time from randomization to the earliest time the participant's scale scores showed a 10 point or greater increase after baseline in any of the 3 symptoms.
Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The QLQ-C30 Global QOL, Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, and Social Functioning each ranged from 0-100 with higher scores indicating a better level of functioning or better quality of life.
Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Change From Baseline Scores in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The QLQ-C30 Appetite loss, Constipation, Diarrhea, Dyspnea, Fatigue, Financial difficulties, Insomnia, Nausea/vomiting, and Pain each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems.
Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Change From Baseline in Lung Cancer Symptom Scores as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)
The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. The QLQ-LC13 Alopecia, Coughing, Dysphagia, Dyspnoea, Haemoptysis, Pain in arm or shoulder, Pain in chest, Pain in other parts, Peripheral neuropathy, and Sore mouth each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems.
Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)-Visual Analog Scale (VAS)
EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a visual analog scale (VAS). The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Change From Baseline in General Health Status as Assessed by EQ-5D-Index
EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a visual analog scale (VAS). EQ-5D summary index is obtained with a formula that weights each level of the 5 dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).
Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Percentage of Participants With Visual Disturbance as Assessed by Visual Symptom Assessment Questionnaire (VSAQ-ALK)
VSAQ-ALK is a self-report measure that was developed to assess the problems of visual disturbances and symptoms may include the appearance of overlapping shadows and after images; shimmering, flashing or trailing lights; strings, streamers, or floaters; as well as hazy or blurry vision. The participants answered "Yes" to the first question (Q1) of VSAQ-ALK "Have you experienced any visual disturbances?" were considered to have experienced visual disturbance and were instructed to complete the rest of the questionnaire. The percentage of participants who responded to Q1 of VSAQ-ALK as "Yes" and as "No" during each study cycle was calculated as (n/N\*)\*100 where N\* was the number of participants who had completed Q1.
Time frame: Cycle 1 Day 1 to end of treatment or withdrawal, no later than 4 weeks (+/- 1 week) from last dose of study medication or when the decision was taken to withdraw from the study (whichever was sooner, assessed up to Cycle 86)
Agreement Between Central Laboratory ALK FISH and ALK IHC Test Results - Molecular Profiling Evaluable
Agreement between central laboratory anaplastic lymphoma kinase (ALK) fluorescence in situ hybridization (FISH) and ALK immunohistochemistry (IHC) test results is based on analysis of participants in the Molecular Profiling (MP) evaluable population that have an ALK IHC result and an ALK FISH result of either positive or negative only. This MP evaluable population included participants who screen failed, which their ALK test results were negative based on FISH test. Tumor tissue samples from these screen failure participants were consented and kept. These samples served as a part of negative sample set for evaluation of IHC test and/or polymerase chain reaction (PCR) to determine ALK fusion events. Participants with FISH results of uninformative and assay not performed and IHC results of valid IHC status not available were excluded from the analysis of agreement between central laboratory ALK FISH and ALK IHC test results.
Time frame: During the screening (less than or equal to 28 days prior to dosing)
Percentage of Participants With Treatment-Emergent Adverse Events (AEs; All Causalities)
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Grade 3 and 4 AEs in below table indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE.
Time frame: From the first dose of study medication up to 28 days after the last dose of study medication or up to the time that a participant died or received subsequent anticancer treatment (maximum duration between first and last dose: 324.4 weeks)
Percentage of Participants With Treatment-Emergent AEs (Treatment Related)
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Grade 3 and 4 AEs in below table indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE.
Time frame: From the first dose of study medication up to 28 days after the last dose of study medication or up to the time that a participant died or received subsequent anticancer treatment (maximum duration between first and last dose: 324.4 weeks)
This phase 3, randomized, open label, multicenter study conducted in 35 centers in 5 countries. A total of 207 actual participants were randomized, 104 in the crizotinib arm and 103 in the chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) arm.
| Milestone | Crizotinib | Chemotherapy |
|---|---|---|
| Started | 104 | 103 |
| Treated | 104 | 101 |
| Completed | 29 | 26 |
| Not completed | 75 | 77 |
| Withdrew: Refused further follow-up | 9 | 12 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Death | 62 | 61 |
| Withdrew: Randomized but not treated | 0 | 2 |
| Withdrew: Long-term follow-up participants who did not respond to the contact from their study sites. | 1 | 2 |
PFS was defined as the time from the date of randomization to the date of the first documentation of objective tumor progression (by IRR) or death on study due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS (in months) was calculated as (first event date - randomization date +1)/30.44. Progression is defined using RECIST v1.1, as at least a 20% increase (including an absolute increase of at least 5 millimeters) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| Months | Crizotinib | Chemotherapy |
|---|---|---|
| Progression-Free Survival (PFS) Based on IRR by Treatment Arm | 11.1 (8.3 to 12.6) | 6.8 (5.7 to 7.0) |
Percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| Percentage of participants | Crizotinib | Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR | 87.5 (79.6 to 93.2) | 45.6 (35.8 to 55.7) |
OS was defined as the time from randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - date of randomization +1)/30.44. For participants who were lost to follow-up or withdrew consent, the OS was censored on the last date that participants were known to be alive.
| Months | Crizotinib | Chemotherapy |
|---|---|---|
| Overall Survival (OS) | 33.7 (26.5 to 42.5) | 32.9 (23.9 to 43.1) |
Disease Control Rate (DCR) at 12 weeks is defined as the percent of participants with CR, PR or stable disease (SD) at 12 weeks according to RECIST version 1.1 as determined by the IRR. The best response of SD can be assigned if SD criteria were met at least once after randomization at a minimum interval of 6 weeks. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| Percentage of participants | Crizotinib | Chemotherapy |
|---|---|---|
| Percentage of Participants With Disease Control at 12 Weeks Based on IRR | 82.7 (74.0 to 89.4) | 73.8 (64.2 to 82.0) |
Probability of survival 1 year and 18 month after randomization. The probability of survival at 1 year was estimated using the Kaplan Meier method and a 2-sided 95% CI for the log \[-log(1-year survival probability)\] was calculated using a normal approximation and then back transformed to give a CI for the 1-year survival probability itself. The probability of survival at 18 months was estimated similarly.
| Percentage of paricipants | Crizotinib | Chemotherapy |
|---|---|---|
| Up to 1 year | 79.3 (70.0 to 86.0) | 79.5 (70.0 to 86.3) |
| Up to 18 months | 71.2 (61.2 to 79.0) | 72.1 (62.0 to 79.9) |
DR was defined as the time from the first documentation of objective tumor response (CR or PR), as determined by the IRR, to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR (in weeks) was calculated as (first date of PD or death - first date of CR or PR +1)/7. DR was only calculated for the subgroup of participants with an objective tumor response.
| Weeks | Crizotinib | Chemotherapy |
|---|---|---|
| Duration of Response (DR) Based on IRR | 44.4 (35.9 to 60.0) | 18.1 (16.7 to 19.9) |
TTR was defined as the time from randomization to first documentation of objective tumor response (CR or PR) as determined by the IRR. For participants proceeding from PR to CR, the onset of PR was taken as the onset of response. TTR was calculated for the subgroup of participants with objective tumor response.
| Weeks | Crizotinib | Chemotherapy |
|---|---|---|
| Time to Tumor Response (TTR) Based on IRR | 6.3 (5.1 to 24.9) | 12.1 (5.7 to 36.1) |
TTP was defined as the time from the date of randomization to the date of the first documentation of objective tumor progression, as determined by IRR. If tumor progression data included more than 1 date, the first date was used. TTP (in months) was calculated as (first event date - randomization date +1)/30.44.
| Months | Crizotinib | Chemotherapy |
|---|---|---|
| Time to Progression (TTP) Based on IRR | 12.0 (8.4 to 15.4) | 6.9 (5.7 to 7.1) |
IC-TTP was defined similarly to TTP, but only considering intracranial disease (excluding extracranial disease) and the progression was determined based on either new brain metastases or progression of existing brain metastases.
| Months | Crizotinib | Chemotherapy |
|---|---|---|
| Intracranial Time to Progression (IC-TTP) Based on IRR | NA (20.8 to NA) | 16.0 (12.6 to NA) |
EC-TTP was defined similarly to TTP, but only considering extracranial disease (excluding intracranial disease) and the progression was determined based on either new extracranial lesions or progression of existing extracranial lesions.
| Months | Crizotinib | Chemotherapy |
|---|---|---|
| Extracranial Time to Progression (EC-TTP) Based on IRR | 18.0 (12.3 to 20.9) | 7.0 (6.0 to 7.1) |
The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. The QLQ-LC13 Coughing, Dyspnoea and Pain in chest each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems. TTD in pain in chest, dyspnea, or cough from the QLQ-LC13 was a composite endpoint defined as the time from randomization to the earliest time the participant's scale scores showed a 10 point or greater increase after baseline in any of the 3 symptoms.
| Months | Crizotinib | Chemotherapy |
|---|---|---|
| Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough Assessed Using Quality of Life Questionnaire Supplement Module for Lung Cancer (QLQ-LC13) | 2.8 (1.4 to 6.9) | 0.3 (0.3 to 0.5) |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The QLQ-C30 Global QOL, Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, and Social Functioning each ranged from 0-100 with higher scores indicating a better level of functioning or better quality of life.
| Units on a scale | Crizotinib | Chemotherapy |
|---|---|---|
| QLQ-C30 Global QoL | 5.0891 (2.53 to 7.64) | -2.3619 (-5.00 to 0.28) |
| QLQ-C30 Cognitive Functioning | -1.1896 (-3.28 to 0.90) | -4.8026 (-6.95 to -2.66) |
| QLQ-C30 Emotional Functioning | 3.7077 (1.76 to 5.66) | 2.0557 (0.04 to 4.07) |
| QLQ-C30 Physical Functioning | 3.7705 (1.97 to 5.57) | -2.9562 (-4.82 to -1.10) |
| QLQ-C30 Role Functioning | 1.0538 (-1.56 to 3.66) | -5.7570 (-8.44 to -3.07) |
| QLQ-C30 Social Functioning | 0.8712 (-2.27 to 4.02) | -4.7228 (-7.96 to -1.49) |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The QLQ-C30 Appetite loss, Constipation, Diarrhea, Dyspnea, Fatigue, Financial difficulties, Insomnia, Nausea/vomiting, and Pain each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems.
| Units on a scale | Crizotinib | Chemotherapy |
|---|---|---|
| QLQ-C30 Appetite loss | -1.5967 (-4.18 to 0.99) | 4.4465 (1.74 to 7.15) |
| QLQ-C30 Constipation | 7.1367 (4.40 to 9.87) | 2.6341 (-0.23 to 5.50) |
| QLQ-C30 Diarrhea | 15.3294 (13.35 to 17.31) | -0.4791 (-2.55 to 1.60) |
| QLQ-C30 Dyspnea | -7.9353 (-10.41 to -5.46) | -0.1903 (-2.75 to 2.37) |
| QLQ-C30 Fatigue | -3.8888 (-6.20 to -1.58) | 2.6028 (0.21 to 5.00) |
| QLQ-C30 Financial Difficulties | -3.2339 (-7.26 to 0.79) | 0.3826 (-3.74 to 4.51) |
| QLQ-C30 Insomnia | -8.3816 (-10.95 to -5.81) | -1.6060 (-4.29 to 1.07) |
| QLQ-C30 Nausea and Vomiting | 4.0796 (2.06 to 6.09) | 6.5986 (4.48 to 8.72) |
| QLQ-C30 Pain | -9.1305 (-11.27 to -6.99) | -0.6956 (-2.90 to 1.51) |
The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. The QLQ-LC13 Alopecia, Coughing, Dysphagia, Dyspnoea, Haemoptysis, Pain in arm or shoulder, Pain in chest, Pain in other parts, Peripheral neuropathy, and Sore mouth each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems.
| Units on a scale | Crizotinib | Chemotherapy |
|---|---|---|
| QLQ-LC13 Alopecia | -2.0837 (-4.41 to 0.24) | 2.7710 (0.37 to 5.18) |
| QLQ-LC13 Coughing | -17.2704 (-19.96 to -14.58) | -10.2748 (-13.07 to -7.48) |
| QLQ-LC13 Dysphagia | 0.5354 (-1.34 to 2.41) | 1.0535 (-0.90 to 3.01) |
| QLQ-LC13 Dyspnoea | -9.0842 (-11.34 to -6.83) | -0.4371 (-2.76 to 1.89) |
| QLQ-LC13 Haemoptysis | -4.3017 (-5.42 to -3.18) | -3.0513 (-4.22 to -1.88) |
| QLQ-LC13 Pain in Arm or Shoulder | -6.8289 (-9.43 to -4.23) | -2.5927 (-5.29 to 0.11) |
| QLQ-LC13 Pain in Chest | -8.3565 (-10.81 to -5.90) | -4.1328 (-6.68 to -1.58) |
| QLQ-LC13 Pain in Other Parts | -4.8475 (-7.22 to -2.48) | -0.2573 (-2.72 to 2.21) |
| QLQ-LC13 Peripheral Neuropathy | 0.1787 (-1.94 to 2.30) | 1.8519 (-0.36 to 4.06) |
| QLQ-LC13 Sore Mouth | 1.5134 (-0.01 to 3.03) | 3.9114 (2.30 to 5.53) |
EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a visual analog scale (VAS). The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
| Units on a scale | Crizotinib | Chemotherapy |
|---|---|---|
| Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)-Visual Analog Scale (VAS) | 3.4209 (1.20 to 5.64) | -0.4927 (-2.75 to 1.77) |
EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a visual analog scale (VAS). EQ-5D summary index is obtained with a formula that weights each level of the 5 dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).
| Units on a scale | Crizotinib | Chemotherapy |
|---|---|---|
| Change From Baseline in General Health Status as Assessed by EQ-5D-Index | 0.0502 (0.02 to 0.08) | 0.0077 (-0.02 to 0.04) |
VSAQ-ALK is a self-report measure that was developed to assess the problems of visual disturbances and symptoms may include the appearance of overlapping shadows and after images; shimmering, flashing or trailing lights; strings, streamers, or floaters; as well as hazy or blurry vision. The participants answered "Yes" to the first question (Q1) of VSAQ-ALK "Have you experienced any visual disturbances?" were considered to have experienced visual disturbance and were instructed to complete the rest of the questionnaire. The percentage of participants who responded to Q1 of VSAQ-ALK as "Yes" and as "No" during each study cycle was calculated as (n/N\*)\*100 where N\* was the number of participants who had completed Q1.
| Percentage of participants | Crizotinib | Chemotherapy |
|---|---|---|
| Baseline: Cycle 1/Day 1 (Answer to Q1: Yes) | 6.8 | 7.1 |
| Baseline: Cycle 1/Day 1 (Answer to Q1: No) | 93.2 | 92.9 |
| Cycle 2/Day 1 (Answer to Q1: Yes) | 51.0 | 13.4 |
| Cycle 2/Day 1 (Answer to Q1: No) | 49.0 | 86.6 |
| Cycle 3/Day 1 (Answer to Q1: Yes) | 46.1 | 11.1 |
| Cycle 3/Day 1 (Answer to Q1: No) | 53.9 | 88.9 |
| Cycle 4/Day 1 (Answer to Q1: Yes) | 43.9 | 14.8 |
| Cycle 4/Day 1 (Answer to Q1: No) | 56.1 | 85.2 |
| Cycle 5/Day 1 (Answer to Q1: Yes) | 35.8 | 13.5 |
| Cycle 5/Day 1 (Answer to Q1: No) | 64.2 | 86.5 |
| Cycle 6/Day 1 (Answer to Q1: Yes) | 37.4 | 10.1 |
| Cycle 6/Day 1 (Answer to Q1: No) | 62.6 | 89.9 |
| Cycle 7/Day 1 (Answer to Q1: Yes) | 36.0 | — |
| Cycle 7/Day 1 (Answer to Q1: No) | 64.0 | — |
| Cycle 8/Day 1 (Answer to Q1: Yes) | 28.1 | — |
| Cycle 8/Day 1 (Answer to Q1: No) | 71.9 | — |
| Cycle 9/Day 1 (Answer to Q1: Yes) | 24.1 | — |
| Cycle 9/Day 1 (Answer to Q1: No) | 75.9 | — |
| Cycle 10/Day 1 (Answer to Q1: Yes) | 23.9 | — |
| Cycle 10/Day 1 (Answer to Q1: No) | 76.1 | — |
| Cycle 11/Day 1 (Answer to Q1: Yes) | 23.5 | — |
| Cycle 11/Day 1 (Answer to Q1: No) | 76.5 | — |
| Cycle 12/Day 1 (Answer to Q1: Yes) | 21.3 | — |
| Cycle 12/Day 1 (Answer to Q1: No) | 78.8 | — |
| Cycle 13/Day 1 (Answer to Q1: Yes) | 25.3 | — |
| Cycle 13/Day 1 (Answer to Q1: No) | 74.7 | — |
| Cycle 14/Day 1 (Answer to Q1: Yes) | 27.0 | — |
| Cycle 14/Day 1 (Answer to Q1: No) | 73.0 | — |
| Cycle 15/Day 1 (Answer to Q1: Yes) | 28.2 | — |
| Cycle 15/Day 1 (Answer to Q1: No) | 71.8 | — |
| Cycle 16/Day 1 (Answer to Q1: Yes) | 28.6 | — |
| Cycle 16/Day 1 (Answer to Q1: No) | 71.4 | — |
| Cycle 17/Day 1 (Answer to Q1: Yes) | 28.6 | — |
| Cycle 17/Day 1 (Answer to Q1: No) | 71.4 | — |
| Cycle 18/Day 1 (Answer to Q1: Yes) | 28.4 | — |
| Cycle 18/Day 1 (Answer to Q1: No) | 71.6 | — |
| Cycle 19/Day 1 (Answer to Q1: Yes) | 28.1 | — |
| Cycle 19/Day 1 (Answer to Q1: No) | 71.9 | — |
| Cycle 20/Day 1 (Answer to Q1: Yes) | 27.9 | — |
| Cycle 20/Day 1 (Answer to Q1: No) | 72.1 | — |
| Cycle 21/Day 1 (Answer to Q1: Yes) | 30.5 | — |
| Cycle 21/Day 1 (Answer to Q1: No) | 69.5 | — |
| Cycle 22/Day 1 (Answer to Q1: Yes) | 29.1 | — |
| Cycle 22/Day 1 (Answer to Q1: No) | 70.9 | — |
| Cycle 23/Day 1 (Answer to Q1: Yes) | 28.6 | — |
| Cycle 23/Day 1 (Answer to Q1: No) | 71.4 | — |
| Cycle 24/Day 1 (Answer to Q1: Yes) | 31.5 | — |
| Cycle 24/Day 1 (Answer to Q1: No) | 68.5 | — |
| Cycle 25/Day 1 (Answer to Q1: Yes) | 32.1 | — |
| Cycle 25/Day 1 (Answer to Q1: No) | 67.9 | — |
| Cycle 26/Day 1 (Answer to Q1: Yes) | 28.8 | — |
| Cycle 26/Day 1 (Answer to Q1: No) | 71.2 | — |
| Cycle 27/Day 1 (Answer to Q1: Yes) | 28.0 | — |
| Cycle 27/Day 1 (Answer to Q1: No) | 72.0 | — |
| Cycle 28/Day 1 (Answer to Q1: Yes) | 30.0 | — |
| Cycle 28/Day 1 (Answer to Q1: No) | 70.0 | — |
| Cycle 29/Day 1 (Answer to Q1: Yes) | 30.0 | — |
| Cycle 29/Day 1 (Answer to Q1: No) | 70.0 | — |
| Cycle 30/Day 1 (Answer to Q1: Yes) | 32.0 | — |
| Cycle 30/Day 1 (Answer to Q1: No) | 68.0 | — |
| Cycle 31/Day 1 (Answer to Q1: Yes) | 24.5 | — |
| Cycle 31/Day 1 (Answer to Q1: No) | 75.5 | — |
| Cycle 32/Day 1 (Answer to Q1: Yes) | 25.0 | — |
| Cycle 32/Day 1 (Answer to Q1: No) | 75.0 | — |
| Cycle 33/Day 1 (Answer to Q1: Yes) | 28.3 | — |
| Cycle 33/Day 1 (Answer to Q1: No) | 71.7 | — |
| Cycle 34/Day 1 (Answer to Q1: Yes) | 27.3 | — |
| Cycle 34/Day 1 (Answer to Q1: No) | 72.7 | — |
| Cycle 35/Day 1 (Answer to Q1: Yes) | 28.6 | — |
| Cycle 35/Day 1 (Answer to Q1: No) | 71.4 | — |
| Cycle 36/Day 1 (Answer to Q1: Yes) | 26.8 | — |
| Cycle 36/Day 1 (Answer to Q1: No) | 73.2 | — |
| Cycle 37/Day 1 (Answer to Q1: Yes) | 27.0 | — |
| Cycle 37/Day 1 (Answer to Q1: No) | 73.0 | — |
| Cycle 38/Day 1 (Answer to Q1: Yes) | 24.3 | — |
| Cycle 38/Day 1 (Answer to Q1: No) | 75.7 | — |
| Cycle 39/Day 1 (Answer to Q1: Yes) | 30.3 | — |
| Cycle 39/Day 1 (Answer to Q1: No) | 69.7 | — |
| Cycle 40/Day 1 (Answer to Q1: Yes) | 25.0 | — |
| Cycle 40/Day 1 (Answer to Q1: No) | 75.0 | — |
| Cycle 41/Day 1 (Answer to Q1: Yes) | 32.3 | — |
| Cycle 41/Day 1 (Answer to Q1: No) | 67.7 | — |
| Cycle 42/Day 1 (Answer to Q1: Yes) | 25.8 | — |
| Cycle 42/Day 1 (Answer to Q1: No) | 74.2 | — |
| Cycle 43/Day 1 (Answer to Q1: Yes) | 24.1 | — |
| Cycle 43/Day 1 (Answer to Q1: No) | 75.9 | — |
| Cycle 44/Day 1 (Answer to Q1: Yes) | 30.0 | — |
| Cycle 44/Day 1 (Answer to Q1: No) | 70.0 | — |
| Cycle 45/Day 1 (Answer to Q1: Yes) | 25.0 | — |
| Cycle 45/Day 1 (Answer to Q1: No) | 75.0 | — |
| Cycle 46/Day 1 (Answer to Q1: Yes) | 27.6 | — |
| Cycle 46/Day 1 (Answer to Q1: No) | 72.4 | — |
| Cycle 47/Day 1 (Answer to Q1: Yes) | 26.9 | — |
| Cycle 47/Day 1 (Answer to Q1: No) | 73.1 | — |
| Cycle 48/Day 1 (Answer to Q1: Yes) | 29.6 | — |
| Cycle 48/Day 1 (Answer to Q1: No) | 70.4 | — |
| Cycle 49/Day 1 (Answer to Q1: Yes) | 29.2 | — |
| Cycle 49/Day 1 (Answer to Q1: No) | 70.8 | — |
| Cycle 50/Day 1 (Answer to Q1: Yes) | 29.2 | — |
| Cycle 50/Day 1 (Answer to Q1: No) | 70.8 | — |
| Cycle 51/Day 1 (Answer to Q1: Yes) | 26.1 | — |
| Cycle 51/Day 1 (Answer to Q1: No) | 73.9 | — |
| Cycle 52/Day 1 (Answer to Q1: Yes) | 29.2 | — |
| Cycle 52/Day 1 (Answer to Q1: No) | 70.8 | — |
| Cycle 53/Day 1 (Answer to Q1: Yes) | 25.0 | — |
| Cycle 53/Day 1 (Answer to Q1: No) | 75.0 | — |
| Cycle 54/Day 1 (Answer to Q1: Yes) | 36.4 | — |
| Cycle 54/Day 1 (Answer to Q1: No) | 63.6 | — |
| Cycle 55/Day 1 (Answer to Q1: Yes) | 29.4 | — |
| Cycle 55/Day 1 (Answer to Q1: No) | 70.6 | — |
| Cycle 56/Day 1 (Answer to Q1: Yes) | 38.9 | — |
| Cycle 56/Day 1 (Answer to Q1: No) | 61.1 | — |
| Cycle 57/Day 1 (Answer to Q1: Yes) | 20.0 | — |
| Cycle 57/Day 1 (Answer to Q1: No) | 80.0 | — |
| Cycle 58/Day 1 (Answer to Q1: Yes) | 35.3 | — |
| Cycle 58/Day 1 (Answer to Q1: No) | 64.7 | — |
| Cycle 59/Day 1 (Answer to Q1: Yes) | 21.4 | — |
| Cycle 59/Day 1 (Answer to Q1: No) | 78.6 | — |
| Cycle 60/Day 1 (Answer to Q1: Yes) | 37.5 | — |
| Cycle 60/Day 1 (Answer to Q1: No) | 62.5 | — |
| Cycle 61/Day 1 (Answer to Q1: Yes) | 23.1 | — |
| Cycle 61/Day 1 (Answer to Q1: No) | 76.9 | — |
| Cycle 62/Day 1 (Answer to Q1: Yes) | 37.5 | — |
| Cycle 62/Day 1 (Answer to Q1: No) | 62.5 | — |
| Cycle 63/Day 1 (Answer to Q1: Yes) | 21.4 | — |
| Cycle 63/Day 1 (Answer to Q1: No) | 78.6 | — |
| Cycle 64/Day 1 (Answer to Q1: Yes) | 35.7 | — |
| Cycle 64/Day 1 (Answer to Q1: No) | 64.3 | — |
| Cycle 65/Day 1 (Answer to Q1: Yes) | 21.4 | — |
| Cycle 65/Day 1 (Answer to Q1: No) | 78.6 | — |
| Cycle 66/Day 1 (Answer to Q1: Yes) | 30.8 | — |
| Cycle 66/Day 1 (Answer to Q1: No) | 69.2 | — |
| Cycle 67/Day 1 (Answer to Q1: Yes) | 25.0 | — |
| Cycle 67/Day 1 (Answer to Q1: No) | 75.0 | — |
| Cycle 68/Day 1 (Answer to Q1: Yes) | 30.8 | — |
| Cycle 68/Day 1 (Answer to Q1: No) | 69.2 | — |
| Cycle 69/Day 1 (Answer to Q1: Yes) | 25.0 | — |
| Cycle 69/Day 1 (Answer to Q1: No) | 75.0 | — |
| Cycle 70/Day 1 (Answer to Q1: Yes) | 30.8 | — |
| Cycle 70/Day 1 (Answer to Q1: No) | 69.2 | — |
| Cycle 71/Day 1 (Answer to Q1: Yes) | 30.0 | — |
| Cycle 71/Day 1 (Answer to Q1: No) | 70.0 | — |
| Cycle 72/Day 1 (Answer to Q1: Yes) | 22.2 | — |
| Cycle 72/Day 1 (Answer to Q1: No) | 77.8 | — |
| Cycle 73/Day 1 (Answer to Q1: Yes) | 22.2 | — |
| Cycle 73/Day 1 (No) | 77.8 | — |
| Cycle 74/Day 1 (Answer to Q1: Yes) | 25.0 | — |
| Cycle 74/Day 1 (Answer to Q1: No) | 75.0 | — |
| Cycle 75/Day 1 (Answer to Q1: Yes) | 22.2 | — |
| Cycle 75/Day 1 (Answer to Q1: No) | 77.8 | — |
| Cycle 76/Day 1 (Answer to Q1: Yes) | 16.7 | — |
| Cycle 76/Day 1 (Answer to Q1: No) | 83.3 | — |
| Cycle 77/Day 1 (Answer to Q1: Yes) | 37.5 | — |
| Cycle 77/Day 1 (Answer to Q1: No) | 62.5 | — |
| Cycle 78/Day 1 (Answer to Q1: Yes) | 20.0 | — |
| Cycle 78/Day 1 (Answer to Q1: No) | 80.0 | — |
| Cycle 79/Day 1 (Answer to Q1: Yes) | 20.0 | — |
| Cycle 79/Day 1 (Answer to Q1: No) | 80.0 | — |
| Cycle 80/Day 1 (Answer to Q1: Yes) | 0.0 | — |
| Cycle 80/Day 1 (Answer to Q1: No) | 100.0 | — |
| Cycle 81/Day 1 (Answer to Q1: Yes) | 0.0 | — |
| Cycle 81/Day 1 (Answer to Q1: No) | 100.0 | — |
| Cycle 82/Day 1 (Answer to Q1: Yes) | 0.0 | — |
| Cycle 82/Day 1 Answer to Q1: (No) | 100.0 | — |
| Cycle 83/Day 1 (Answer to Q1: Yes) | 0.0 | — |
| Cycle 83/Day 1 (Answer to Q1: No) | 100.0 | — |
| Cycle 84/Day 1 (Answer to Q1: Yes) | 0.0 | — |
| Cycle 84/Day 1 (Answer to Q1: No) | 100.0 | — |
| Cycle 86/Day 1 (Answer to Q1: Yes) | 0.0 | — |
| Cycle 86/Day 1 (Answer to Q1: No) | 100.0 | — |
Agreement between central laboratory anaplastic lymphoma kinase (ALK) fluorescence in situ hybridization (FISH) and ALK immunohistochemistry (IHC) test results is based on analysis of participants in the Molecular Profiling (MP) evaluable population that have an ALK IHC result and an ALK FISH result of either positive or negative only. This MP evaluable population included participants who screen failed, which their ALK test results were negative based on FISH test. Tumor tissue samples from these screen failure participants were consented and kept. These samples served as a part of negative sample set for evaluation of IHC test and/or polymerase chain reaction (PCR) to determine ALK fusion events. Participants with FISH results of uninformative and assay not performed and IHC results of valid IHC status not available were excluded from the analysis of agreement between central laboratory ALK FISH and ALK IHC test results.
| Participants | Participants With Positive ALK FISH Status | Participants With Negative ALK FISH Status |
|---|---|---|
| Participants with Positive ALK IHC Status | 218 (91.4 to 94.9) | 31 |
| Participants with Negative ALK IHC Status | 20 | 502 |
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Grade 3 and 4 AEs in below table indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE.
| Percentage of participants | Crizotinib | Chemotherapy |
|---|---|---|
| AEs | 99.0 | 99.0 |
| SAEs | 44.2 | 12.9 |
| Grade 3/4 AEs | 58.7 | 52.5 |
| Grade 5 AEs | 22.1 | 2.0 |
| AEs associated with permanent discontinuation | 26.9 | 4.0 |
| AEs associated with dose reduction | 14.4 | 7.9 |
| AEs associated with temporary discontinuation | 39.4 | 37.6 |
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Grade 3 and 4 AEs in below table indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE.
| Percentage of participants | Crizotinib | Chemotherapy |
|---|---|---|
| AEs | 98.1 | 96.0 |
| Serious AEs | 8.7 | 3.0 |
| Grade 3/4 AEs | 43.3 | 40.6 |
| Grade 5 AEs | 1.9 | 0 |
| AEs associated with permanent discontinuation | 5.8 | 1.0 |
| AEs associated with dose reduction | 13.5 | 7.9 |
| AEs associated with temporary discontinuation | 28.8 | 31.7 |
Collected over From the first dose of study medication up to 28 days after the last dose of study medication or up to the time that a participant died or received subsequent anticancer treatment (maximum duration between first and last dose: 324.4 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Crizotinib | 62/104 (59.6%) | 46/104 (44.2%) | 103/104 (99%) |
| Chemotherapy | 61/101 (60.4%) | 13/101 (12.9%) | 100/101 (99%) |
| Event | Crizotinib | Chemotherapy |
|---|---|---|
| Disease progressionGeneral disorders | 15/104 | 1/101 |
| PneumoniaInfections and infestations | 5/104 | 1/101 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/104 | 0/101 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/104 | 2/101 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/104 | 2/101 |
| DysphagiaGastrointestinal disorders | 2/104 | 0/101 |
| DeathGeneral disorders | 2/104 | 1/101 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 2/104 | 0/101 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/104 | 1/101 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/104 | 0/101 |
| Event | Crizotinib | Chemotherapy |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 69/104 | 45/101 |
| DiarrhoeaGastrointestinal disorders | 63/104 | 9/101 |
| Aspartate aminotransferase increasedInvestigations | 62/104 | 35/101 |
| VomitingGastrointestinal disorders | 61/104 | 46/101 |
| White blood cell count decreasedInvestigations | 43/104 | 56/101 |
| NauseaGastrointestinal disorders | 56/104 | 50/101 |
| AnaemiaBlood and lymphatic system disorders | 20/104 | 49/101 |
| Visual impairmentEye disorders | 42/104 | 8/101 |
| Neutrophil count decreasedInvestigations | 40/104 | 33/101 |
| NeutropeniaBlood and lymphatic system disorders | 21/104 | 37/101 |
| Age, Continuous(Years) | Crizotinib | Chemotherapy | Total |
|---|---|---|---|
| Mean | 48.2 ± 10.6 | 48.9 ± 11.2 | 48.5 ± 10.9 |
| Sex: Female, Male(Participants) | Crizotinib | Chemotherapy | Total |
|---|---|---|---|
| Female | 54 | 60 | 114 |
| Male | 50 | 43 | 93 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2012 to primary completion in Jun 2015, 33 months.
Results were first posted in Mar 2017, 1 year 8 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 33 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crizotinib
Carcinoma, Non-Small-Cell Lung →